Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Non Operating Income (2020 - 2025)

Oncology Institute's Non Operating Income history spans 6 years, with the latest figure at $23.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 690.16% year-over-year to $23.1 million; the TTM value through Dec 2025 reached $16.0 million, up 319.45%, while the annual FY2025 figure was -$925000.0, 153.42% down from the prior year.
  • Non Operating Income reached $23.1 million in Q4 2025 per TOI's latest filing, up from -$403000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $37.9 million in Q1 2022 to a low of -$5.9 million in Q2 2025.
  • Average Non Operating Income over 5 years is $4.2 million, with a median of $61000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: soared 17231.25% in 2022, then crashed 9230.56% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$80000.0 in 2021, then skyrocketed by 17231.25% to $13.7 million in 2022, then crashed by 127.58% to -$3.8 million in 2023, then skyrocketed by 177.43% to $2.9 million in 2024, then surged by 690.16% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Non Operating Income are $23.1 million (Q4 2025), -$403000.0 (Q3 2025), and -$5.9 million (Q2 2025).